Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Prostate Cancer

  Free Subscription


24.09.2018

1 AJR Am J Roentgenol
2 Anticancer Res
1 BJU Int
1 BMC Urol
3 Cancer Lett
5 Cancer Res
3 Clin Cancer Res
9 Eur Urol
1 Int J Cancer
2 Int J Oncol
1 Int J Radiat Oncol Biol Phys
2 Int J Urol
1 J Magn Reson Imaging
1 J Nucl Med
9 J Urol
1 Oncogene
3 Oncol Rep
2 PLoS One
1 Proc Natl Acad Sci U S A
1 Prostate
2 Radiology
1 Urol Int


   Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AJR Am J Roentgenol

  1. WOO S, Suh CH, Kim SY, Cho JY, et al
    Head-to-Head Comparison Between Biparametric and Multiparametric MRI for the Diagnosis of Prostate Cancer: A Systematic Review and Meta-Analysis.
    AJR Am J Roentgenol. 2018 Sep 21:W1-W15. doi: 10.2214/AJR.18.19880.
    PubMed     Text format     Abstract available


    Anticancer Res

  2. ONISHI T, Sekito S, Terabe T, Shibahara T, et al
    A Combination of Findings Obtained from Pre- and Postoperative Imaging Predict Recovery of Urinary Continence After Non-nerve-sparing Laparoscopic Radical Prostatectomy.
    Anticancer Res. 2018;38:5525-5530.
    PubMed     Text format     Abstract available

  3. DADHANIA S, Alonzi R, Douglas S, Gogbashian A, et al
    Single-centre Experience of Use of Radium 223 with Clinical Outcomes Based on Number of Cycles and Bone Marrow Toxicity.
    Anticancer Res. 2018;38:5423-5427.
    PubMed     Text format     Abstract available


    BJU Int

  4. VAN NIEUWENHOVE S, Saussez TP, Thiry S, Trefois P, et al
    Prospective comparison of a fast 1.5T biparametric to the 3.0T multi-parametric ESUR magnetic resonance imaging protocol as triage test for men at risk of prostate cancer.
    BJU Int. 2018 Sep 21. doi: 10.1111/bju.14538.
    PubMed     Text format     Abstract available


    BMC Urol

  5. BODY JJ, von Moos R, Niepel D, Tombal B, et al
    Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion.
    BMC Urol. 2018;18:81.
    PubMed     Text format     Abstract available


    Cancer Lett

  6. WANG S, Ekoue DN, Raj GV, Kittler R, et al
    Targeting the turnover of oncoproteins as a new avenue for therapeutics development in castration-resistant prostate cancer.
    Cancer Lett. 2018 Sep 11. pii: S0304-3835(18)30565.
    PubMed     Text format     Abstract available

  7. NIU Y, Guo C, Wen S, Tian J, et al
    ADT with antiandrogens in prostate cancer induces adverse effect of increasing resistance, neuroendocrine differentiation and tumor metastasis.
    Cancer Lett. 2018 Sep 15. pii: S0304-3835(18)30575.
    PubMed     Text format     Abstract available

  8. RUSSO JW, Liu X, Ye H, Calagua C, et al
    Phosphorylation of Androgen Receptor Serine 81 is Associated with its Reactivation in Castration-Resistant Prostate Cancer.
    Cancer Lett. 2018 Sep 11. pii: S0304-3835(18)30569.
    PubMed     Text format     Abstract available


    Cancer Res

  9. JARATLERDSIRI W, Chan EKF, Gong T, Petersen DC, et al
    Whole Genome Sequencing Reveals Elevated Tumor Mutational Burden and Initiating Driver Mutations in African Men with Treatment-Naive, High-Risk Prostate Cancer.
    Cancer Res. 2018 Sep 14. pii: 0008-5472.CAN-18-0254.
    PubMed     Text format     Abstract available


  10. Retraction: Antitumor and Antimetastatic Activities of Docetaxel Are Enhanced by Genistein through Regulation of Osteoprotegerin/Receptor Activator of Nuclear Factor-kappaB (RANK)/RANK Ligand/MMP-9 Signaling in Prostate Cancer.
    Cancer Res. 2018;78:5475.
    PubMed     Text format    


  11. Retraction: Down-regulation of Androgen Receptor by 3,3'-Diindolylmethane Contributes to Inhibition of Cell Proliferation and Induction of Apoptosis in Both Hormone-Sensitive LNCaP and Insensitive C4-2B Prostate Cancer Cells.
    Cancer Res. 2018;78:5473.
    PubMed     Text format    


  12. Retraction: Inhibition of Angiogenesis and Invasion by 3,3'-Diindolylmethane Is Mediated by the Nuclear Factor-kappaB Downstream Target Genes MMP-9 and uPA that Regulated Bioavailability of Vascular Endothelial Growth Factor in Prostate Cancer.
    Cancer Res. 2018;78:5471.
    PubMed     Text format    


  13. Editor's Note: In vitro and In vivo Molecular Evidence for Better Therapeutic Efficacy of ABT-627 and Taxotere Combination in Prostate Cancer.
    Cancer Res. 2018;78:5465.
    PubMed     Text format    


    Clin Cancer Res

  14. FERRARI AC, Alumkal JJ, Stein MN, Taplin ME, et al
    Epigenetic Therapy with Panobinostat Combined with Bicalutamide Re-challenge in Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2018 Sep 17. pii: 1078-0432.CCR-18-1589.
    PubMed     Text format     Abstract available

  15. GAO X, Dai C, Huang S, Tang J, et al
    Functional silencing of HSD17B2 in prostate cancer promotes disease progression.
    Clin Cancer Res. 2018 Sep 18. pii: 1078-0432.CCR-18-2392.
    PubMed     Text format     Abstract available

  16. BELTRAN H, Oromendia C, Danila DC, Montgomery B, et al
    A phase II trial of the aurora kinase A inhibitor alisertib for patients with castration resistant and neuroendocrine prostate cancer: efficacy and biomarkers.
    Clin Cancer Res. 2018 Sep 19. pii: 1078-0432.CCR-18-1912.
    PubMed     Text format     Abstract available


    Eur Urol

  17. TILKI D, Evans CP
    The Decipher Genomic Classifier Independently Improves Prognostication for Patients After Prostatectomy.
    Eur Urol. 2018;73:176-177.
    PubMed     Text format    

  18. CHIN JL
    Robotic-assisted Radical Prostatectomy for High-risk Cancer: Time for "Sexta-fecta".
    Eur Urol. 2018;73:224-225.
    PubMed     Text format    

  19. PARKER C, Sydes MR
    Salvage Treatment After Radical Prostatectomy.
    Eur Urol. 2018;73:166-167.
    PubMed     Text format    

  20. VALERIO M, Emberton M, Ahmed HU
    Re: Henk G. van der Poel, Roderick C.N. van den Bergh, Erik Briers, et al. Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018. Eur Urol 2018;74:84-91.
    Eur Urol. 2018 Sep 14. pii: S0302-2838(18)30646.
    PubMed     Text format    

  21. WEINER AB, Schaeffer EM, Eggener SE
    "Real-world" Practice Makes Perfect: Ensuring the Active Component of Active Surveillance for Prostate Cancer.
    Eur Urol. 2018 Sep 14. pii: S0302-2838(18)30643.
    PubMed     Text format    

  22. SIVA S, Bressel M, Murphy DG, Shaw M, et al
    Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial.
    Eur Urol. 2018;74:455-462.
    PubMed     Text format     Abstract available

  23. MCKIERNAN J, Donovan MJ, Margolis E, Partin A, et al
    A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy.
    Eur Urol. 2018 Sep 17. pii: S0302-2838(18)30604.
    PubMed     Text format     Abstract available

  24. VAN DER POEL HG, van den Bergh RCN, Briers E, Cornford P, et al
    Reply to Massimo Valerio, Mark Emberton, and Hashim U. Ahmed's Letter to the Editor re: Henk G. van der Poel, Roderick C.N. van den Bergh, Erik Briers, et al. Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Posi
    Eur Urol. 2018 Sep 17. pii: S0302-2838(18)30645.
    PubMed     Text format    

  25. PRESTON MA, Gerke T, Carlsson SV, Signorello L, et al
    Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men.
    Eur Urol. 2018 Sep 17. pii: S0302-2838(18)30627.
    PubMed     Text format     Abstract available


    Int J Cancer

  26. HU B, Hu H, Yin M, Sun Z, et al
    Sertad1 promotes prostate cancer progression through binding androgen receptor ligand binding domain.
    Int J Cancer. 2018 Sep 19. doi: 10.1002/ijc.31877.
    PubMed     Text format     Abstract available


    Int J Oncol

  27. NUNEZ-IGLESIAS MJ, Novio S, Garcia-Santiago C, Cartea ME, et al
    Effects of 3-butenyl isothiocyanate on phenotypically different prostate cancer cells.
    Int J Oncol. 2018;53:2213-2223.
    PubMed     Text format     Abstract available

  28. APOSTOLATOS AH, Ratnayake WS, Win-Piazza H, Apostolatos CA, et al
    Inhibition of atypical protein kinase Ciota effectively reduces the malignancy of prostate cancer cells by downregulating the NF-kappaB signaling cascade.
    Int J Oncol. 2018;53:1836-1846.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  29. SPRATT DE
    Evidence-based Risk Stratification to Guide Hormone Therapy Use With Salvage Radiation Therapy for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2018;102:556-560.
    PubMed     Text format    


    Int J Urol

  30. CHOI SY, Ryu J, You D, Hong JH, et al
    Simple risk assessment in prostate cancer patients treated with primary androgen deprivation therapy: The Korean Cancer Study of the Prostate risk classification.
    Int J Urol. 2018 Sep 20. doi: 10.1111/iju.13800.
    PubMed     Text format     Abstract available

  31. SCHIAVINA R, Chessa F, Borghesi M, Gaudiano C, et al
    State-of-the-art imaging techniques in the management of preoperative staging and re-staging of prostate cancer.
    Int J Urol. 2018 Sep 20. doi: 10.1111/iju.13797.
    PubMed     Text format     Abstract available


    J Magn Reson Imaging

  32. CHEN T, Li M, Gu Y, Zhang Y, et al
    Prostate Cancer Differentiation and Aggressiveness: Assessment With a Radiomic-Based Model vs. PI-RADS v2.
    J Magn Reson Imaging. 2018 Sep 19. doi: 10.1002/jmri.26243.
    PubMed     Text format     Abstract available


    J Nucl Med

  33. SCHOTTELIUS M, Wurzer A, Wissmiller K, Beck R, et al
    Synthesis and preclinical characterization of the PSMA-targeted hybrid tracer PSMA-I&F for nuclear and fluorescence imaging of prostate cancer.
    J Nucl Med. 2018 Sep 20. pii: jnumed.118.212720. doi: 10.2967/jnumed.118.212720.
    PubMed     Text format     Abstract available


    J Urol

  34. LOEB S, Folkvaljon Y, Bratt O, Robinson D, et al
    Defining Intermediate-Risk Prostate Cancer Suitable for Active Surveillance.
    J Urol. 2018 Sep 18. pii: S0022-5347(18)43908-0. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available

  35. RAJARUBENDRA N, Almeida F, Manojlovic Z, Ohe C, et al
    Histologic Validation of (11)Carbon-Acetate Positron Emission Tomography/Computer Tomography in Detecting Lymph Node Metastases in Prostate Cancer.
    J Urol. 2018 Sep 12. pii: S0022-5347(18)43871-2. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available

  36. BALAKRISHNAN AS, Palmer NR, Fergus KB, Gaither TW, et al
    Minority recruitment trends in phase III prostate cancer clinical trials (2003-2014): progress and critical areas for improvement.
    J Urol. 2018 Sep 12. pii: S0022-5347(18)43872-4. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available

  37. RESNICK MJ
    Re: Using Medicare Claims to Examine Long-Term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial.
    J Urol. 2018;200:689.
    PubMed     Text format    

  38. THOMSEN FB, Jakobsen H, Langkilde NC, Borre M, et al
    Active surveillance for localized prostate cancer. Nationwide, observational study.
    J Urol. 2018 Sep 18. pii: S0022-5347(18)43911-0. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available

  39. TANEJA SS
    Re: Short-Term Effects of Transdermal Estradiol in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer: A Randomized Placebo-Controlled Trial.
    J Urol. 2018;200:698-699.
    PubMed     Text format    

  40. TANEJA SS
    Re: Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial.
    J Urol. 2018;200:699.
    PubMed     Text format    

  41. ATALA A
    Re: Compartmentalized Activities of the Pyruvate Dehydrogenase Complex Sustain Lipogenesis in Prostate Cancer.
    J Urol. 2018;200:701-702.
    PubMed     Text format    

  42. TANEJA SS
    Re: MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis.
    J Urol. 2018;200:697-699.
    PubMed     Text format    


    Oncogene

  43. WARREN AY, Massie CE, Watt K, Luko K, et al
    A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer.
    Oncogene. 2018 Sep 20. pii: 10.1038/s41388-018-0501.
    PubMed     Text format     Abstract available


    Oncol Rep

  44. KOU R, Zhao J, Gogoi P, Carskadon S, et al
    Enrichment and mutation detection of circulating tumor cells from blood samples.
    Oncol Rep. 2018;39:2537-2544.
    PubMed     Text format     Abstract available

  45. TAKAO A, Yoshikawa K, Karnan S, Ota A, et al
    Generation of PTENknockout (/) murine prostate cancer cells using the CRISPR/Cas9 system and comprehensive gene expression profiling.
    Oncol Rep. 2018;40:2455-2466.
    PubMed     Text format     Abstract available

  46. WU S, Huang J, Hui K, Yue Y, et al
    2'Hydroxyflavanone inhibits epithelialmesenchymal transition, and cell migration and invasion via suppression of the Wnt/betacatenin signaling pathway in prostate cancer.
    Oncol Rep. 2018;40:2836-2843.
    PubMed     Text format     Abstract available


    PLoS One

  47. CHOI YJ, Lee DH, Han KD, Yoon H, et al
    Is nonalcoholic fatty liver disease associated with the development of prostate cancer? A nationwide study with 10,516,985 Korean men.
    PLoS One. 2018;13:e0201308.
    PubMed     Text format     Abstract available

  48. MILOSAVLJEVIC V, Haddad Y, Merlos Rodrigo MA, Moulick A, et al
    Correction: The Zinc-Schiff Base-Novicidin Complex as a Potential Prostate Cancer Therapy.
    PLoS One. 2018;13:e0204441.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A


  49. Correction for Chen et al., Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13.
    Proc Natl Acad Sci U S A. 2018;115:E9025.
    PubMed     Text format    


    Prostate

  50. LIU J, Ding D, Jiang Z, Du T, et al
    Long non-coding RNA CCAT1/miR-148a/PKCzeta prevents cell migration of prostate cancer by altering macrophage polarization.
    Prostate. 2018 Sep 16. doi: 10.1002/pros.23716.
    PubMed     Text format     Abstract available


    Radiology

  51. HICKS RM, Simko JP, Westphalen AC, Nguyen HG, et al
    Diagnostic Accuracy of (68)Ga-PSMA-11 PET/MRI Compared with Multiparametric MRI in the Detection of Prostate Cancer.
    Radiology. 2018 Sep 18:180788. doi: 10.1148/radiol.2018180788.
    PubMed     Text format     Abstract available

  52. CIVELEK AC
    (68)Ga-PSMA-11 PET: Better at Detecting Prostate Cancer than Multiparametric MRI?
    Radiology. 2018 Sep 18:181981. doi: 10.1148/radiol.2018181981.
    PubMed     Text format    


    Urol Int

  53. ROSENHAMMER B, Lausenmeyer EM, Mayr R, Burger M, et al
    Holmium Laser Enucleation of the Prostate Provides Similar Incidental Prostate Cancer Detection Rates as Open Prostatectomy: A Matched Pair Analysis.
    Urol Int. 2018 Sep 20:1-5. doi: 10.1159/000492923.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: